Exel

Exel is a supply chain and logistics company operating in North America and Europe. Exel is wholly owned by the German firm Deutsche Post DHL. It reports annual revenues of about $4.2 billion.

History

The company has its origins in several independent warehouse and transportation management companies in the United States which were acquired in 1985 by NFC plc (formerly the National Freight Consortium, the nationalised UK transportation business created by the post-war Labour government). The new company was re-branded Exel and the Americas headquarters was established in Westerville, Ohio, in 1992.

By the year 2000, Exel had grown and expanded operations to include Canada, Latin America and South America. Its portfolio of solutions also grew to include transportation management, freight consolidation, contract packaging, contract manufacturing, demand planning and other supply chain services. In May 2000 NFC plc merged with Ocean Group plc and, adopting the name of its American subsidiary, became Exel plc. In 2004 Exel plc acquired Tibbett & Britten, a leading UK-based contract logistics business, for $710m. On 14 December 2005 Deutsche Post announced the completion of the acquisition of Exel plc.

Foretinib

Foretinib is an experimental drug candidate for the treatment of cancer. It was discovered by Exelixis and is under development by GlaxoSmithKline. About 10 Phase II clinical trials have been run.As of October 2015 no phase III trials are registered.

Foretinib is an inhibitor of the kinase enzymes c-Met and vascular endothelial growth factor receptor 2 (VEGFR-2).

See also

References